Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
A review of the literature on the use of the genetically engineered biological drug Skyrizi (INN: risankizumab) for the treatment of psoriasis in patients is presented. The problem of high dissatisfaction of patients with the available means (methods) of therapy for this dermatosis is discussed. Inh...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Veröffentlicht: |
State Scientific Center of Dermatovenereology and Cosmetology,
2022-09-01T00:00:00Z.
|
| Schlagworte: | |
| Online-Zugang: | Connect to this object online. |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Online
Connect to this object online.3rd Floor Main Library
| Signatur: |
A1234.567 |
|---|---|
| Exemplar 1 | Verfügbar |